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Summary
Three neurokinin (NK) antagonist pharmacophore models (Models 1–3) accounting for hydrogen bonding groups
in the ‘head’ and ‘tail’ of NK receptor ligands have been developed by use of a new procedure for treatment
of hydrogen bonds during superimposition. Instead of modelling the hydrogen bond acceptor vector in the strict
direction of the lone pair, an angle is allowed between the hydrogen bond acceptor direction and the ideal lone
pair direction. This approach adds flexibility to hydrogen bond directions and produces more realistic RMS values.
By using this approach, two novel pharmacophore models were derived (Models 2 and 3) and a hydrogen bond
acceptor was added to a previously published NK2 pharmacophore model [Poulsen et al., J. Comput.-Aided Mol.
Design, 16 (2002) 273] (Model 1). Model 2 as well as Model 3 are described by seven pharmacophore elements:
three hydrophobic groups, three hydrogen bond acceptors and a hydrogen bond donor. Model 1 contains the same
hydrophobic groups and hydrogen bond donor as Models 2 and 3, but only one hydrogen bond acceptor. The
hydrogen bond acceptors and donor are represented as vectors. Two of the hydrophobic groups are always aromatic
rings whereas the other hydrophobic group can be either aromatic or aliphatic. In Model 1 the antagonists bind in
an extended conformation with two aromatic rings in a parallel displaced and tilted conformation. Model 2 has the
same two aromatic rings in a parallel displaced conformation whereas Model 3 has the rings in an edge to face
conformation. The pharmacophore models were evaluated using both a structure (NK receptor homology models)
and a ligand based approach. By use of exhaustive conformational analysis (MMFFs force field and the GB/SA
hydration model) and least-squares molecular superimposition studies, 21 non-peptide antagonists from several
structurally diverse classes were fitted to the pharmacophore models. More antagonists could be fitted to Model 2
with a low RMS and a low conformational energy penalty than to Models 1 and 3. Pharmacophore Model 2 was
also able to explain the NK1, NK2 and NK3 subtype selectivity of the compounds fitted to the model. Three NK
7TM receptor models were constructed, one for each receptor subtype. The location of the antagonist binding site
in the three NK receptor models is identical. Compounds fitted to pharmacophore Model 2 could be docked into
the NK1, NK2 and NK3 receptor models after adjustment of the conformation of the flexible linker connecting the
head and tail. Models 1 and 3 are not compatible with the receptor models.
Introduction
The neurokinin receptors (NKRs) are peptides com-
posed of 350 to 500 amino acids. They belong to the
superfamily of G-protein coupled receptors (GPCRs)
[1]. Three NKR subtypes, NK1, NK2 and NK3, have
∗To whom correspondence should be addressed. E-mail:
tl@dfuni.dk
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been identified by molecular cloning and sequence
analysis. They are characterised by their endogenous
ligands. NK1 has highest affinity for substance P, NK2
has highest affinity for NKA and NK3 has highest
affinity for NKB [1]. Most of the published NK ant-
agonists contain at least two ring systems connected
by a linker holding a hydrogen bond acceptor. We
define this part of the NK antagonists as the head frag-
ment, and the rest is defined as the tail (Figure 1).
The tail of the majority of NK antagonists contains a
basic nitrogen, a hydrophobic group and a hydrogen
bond acceptor. We have previously reported an NK2
pharmacophore model (Figure 2) [2]. In this model,
the antagonists bind in an extended conformation with
two aromatic groups in a parallel displaced and tilted
conformation [3] (A and B in Figure 2). The model
consists of an additional hydrophobic group and a hy-
drogen bond donor represented as a vector (C and D
in Figure 2, respectively). Most of the studied NK ant-
agonists have a piperidine ring in the tail. The most
probable orientation of pharmacophore element C is
equatorial relative to the piperidine ring. This model
agrees with NK1/NK2 and NK2/NK3 receptor model
studies [4, 5]. However, a serious drawback of the
model which was made clear to us through an exten-
ded search for and analysis of NK receptor antagonists
is that it does not account for the importance of hy-
drogen bond accepting groups in the head and tail of
NK antagonists. The importance of such groups is, for
example, demonstrated by compounds 2 and 34. In
34, the amide group in the tail of 2 has been removed
and the compound displays a more than 200-fold de-
crease in affinity. All attempts to add hydrogen bond
acceptor pharmacophore elements to the head and tail
part of the ligands proved futile if the positions and
orientations of the pharmacophore elements were kept
the same as in the previously reported model. Thus,
in order to investigate if such hydrogen bonding can
be accounted for, the conformational properties of the
ligands have been re-investigated, searching for altern-
ative positions and orientations of the pharmacophore
elements.
To add some flexibility to hydrogen bond direc-
tions in the molecular superimpositions, we have in
the present study used a procedure in which an angle
is allowed between the hydrogen bond acceptor direc-
tion and the strict lone pair direction (Figure 3). This
procedure results in more realistic RMS values and
more pharmacophore elements can be incorporated in
the models. The procedure is similar to that used in
programs for 3D database searching where the end-
Figure 1. Definition of fragments with compound 2 as an example.
Centroids, lone pairs and ‘+’ mark the selected pharmacophore
elements A–G.
point of the hydrogen bond vector is allowed to reside
inside a sphere. This is equivalent to allow for both an
interval on the angle between the hydrogen bond and
the lone pair direction and an interval on the length of
the vector.
By using this procedure for treatment of hydrogen
bonds during superimposition we have now developed
three alternative pharmacophore models that incorpor-
ate these hydrogen bond acceptors. The performance
of these alternative models has been assessed by fitting
21 non-peptide antagonists to the model and addition-
ally by docking the ligands to homology models of the
subtypes of the NK receptor, guided by results from
mutational studies.
As is the case for most GPCRs, NKRs have not
yet been crystallised, so no experimental structures
are available. However, the X-ray structure of the
GPCR bovine rhodopsin has recently been published
[6] and the NKRs have sufficient sequence homo-
logy to bovine rhodopsin that an alignment can be
made. The GPCRs contain seven transmembrane α-
helices (7TM) of approximately 25 residues length.
The helices are connected by intra- and extracellular
loops. The N-terminal is located on the extracellular
side whereas the C-terminal extends into the cyto-
plasm. The loop regions and the N- and C-termini
are surrounded by an aqueous environment and consist
primary of hydrophilic amino acids. The 7TM region
is in a lipid environment and consists mainly of hy-
drophobic amino acids. Some experimental work has
been published from which structural information of
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the NKR has been obtained. Elling et al. [7, 8] have
performed extensive mutagenesis work to identify zinc
ion binding sites in the NK1R. Donnelly et al. [9]
have made a Asp79Asn + Asn303Asp NK2R double
mutant and they conclude that there is a direct inter-
action between the side chains of the two residues.
That places TM2 and TM7 in contact, and the relative
orientation of the two helices can be deduced.
Several receptor modelling studies of the NK1R [4,
10–13], the NK2R [4, 5, 14, 15] and the NK3R [5]
have been published. These models are based on the
bacteriorhodopsin cryo electron microscopy structure
by Henderson et al. [16] or the rhodopsin structure
by Baldwin et al. [17]. Bacteriorhodopsin is a proton
pump, not a GPCR, and the sequence identity with
any known GPCR is too low for sequence based align-
ment. Furthermore, the resolution of these structures
is too low to provide the atomic coordinates directly.
Thus, bacteriorhodopsin is not an ideal template for
modelling GPCRs. Rhodopsin is a true GPCR. Bald-
win’s rhodopsin model is based on a cryo microscopy
electron density map of frog rhodopsin [18], but the
resolution is too low to provide atomic coordinates dir-
ectly. Using the recently published bovine rhodopsin
X-ray structure (PDB file 1F88) [6] as a template is
expected to produce better GPCR models. Our NKR
models were used to evaluate the pharmacophore
models. The conformations of compounds manually
docked into the receptor models were compared to the
pharmacophore models and the pharmacophore ele-
ments were compared to specific interactions observed
in the receptor-ligands complex.
The results of the pharmacophore and receptor
modelling studies have been used to discuss the mo-
lecular determinants for NK receptor subtype selectiv-
ity.
Computational methods
Force fields, conformational analysis and calculation
of conformational energies
Conformational space was searched by using the
Monte Carlo Multiple Minimum (MCMM) method
as implemented in MacroModel 7.1 [19]. Force field
calculations were carried out using the MMFF94s
force field, the GB/SA hydration model [20, 21] and
the truncated Newton conjugate gradient algorithm
(TNCG) as implemented in MacroModel. The con-
formational energy penalties were calculated as the
difference in internal energy between the putative bio-
active conformation and the global energy conforma-
tion obtained for aqueous solution (i.e. by subtracting
the energy of the global energy minimum in solution
excluding the hydration energy from the energy of the
putative bioactive conformation) [22]. The solvation
energy was calculated by using the GB/SA hydration
model [20, 21]. No compound had a solvation energy
that differed markedly from the other compounds. A
more detailed description of conformational search,
force fields and calculation of the conformational
energy penalty is given in [2].
Superimposition studies
Three hydrophobic rings, one hydrogen bond donor
(in most cases the protonated nitrogen atom of an
amine) and three hydrogen bond acceptors (two of
which are connected to the same carbonyl oxygen)
were chosen as pharmacophore elements. For each
of the hydrophobic rings, centroids were constructed.
The compounds were first fitted to the pharmacophore
model using only these centroids as fitting points.
In order to include hydrogen bonding and allow
for flexibility in the directions of hydrogen bonds, the
following procedure was then employed.
(1) Dummy atoms were placed 2.8 Å from the
donor/acceptor atoms in the direction of the putat-
ive hydrogen bond interaction vectors defined by the
pharmacophore model. Thus, the ideal hydrogen bond
directions defined by the directions of lone pairs were
not employed.
(2) The compounds were then again fitted to the phar-
macophore models now using both the centroids and
the dummy atoms described above as fitting points.
The RMS values in Tables 1 and 3 were obtained from
this second fit. The hydrogen bond donor and acceptor
atoms in the molecules were not used in the superim-
position.
(3) In order to evaluate the angle of deviation from
an ideal hydrogen bond direction, a second hydro-
gen bonding site point was represented by a dummy
atom 2.8 Å from the donor/acceptor atom but now
in the direction of the nitrogen-hydrogen bond (for
pharmacophore element D) or the lone pair (for phar-
macophore elements E, F and G).
(4) The angle of deviation between the actual hydro-
gen bonding direction and the ideal direction was then
calculated. This angle, ϕ, is defined in Figure 3 where
pharmacophore element F in the head fragment of
compound 4 is used as an example.
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Least-squares rigid body molecular superimposi-
tions were performed using the MacroModel program.
The superimpositions were evaluated in terms of RMS
values of the fitting points. An RMS value of 0.6 Å
has been used as a soft indicator to determine whether
a fit is acceptable or not. The aromatic pharmacophore
elements were fitted in a coplanar orientation if ener-
getically possible. The RMS values do not give any
measure of this coplanarity since only the centroids
are superimposed.
DFT calculations
The program Jaguar 4.1 [23] was used for B3LYP DFT
energy minimisation. The basis set was 6-31G∗∗ and
accuracy level was set to ‘accurate’. Otherwise default
parameters were used.
Receptor modelling
The sequence alignment produced for the NKRs was
similar to the one obtained from the GPCRDB [24]
but slightly modified in the loop regions [25]. NK1R,
NK2R and NK3R models were constructed by the it-
erative distance geometry method of Pogozheva et al.
[26]. This approach utilises the program DIANA [27]
to construct a protein structure from torsional and dis-
tance constraints. The bovine rhodopsin X-ray struc-
ture (PDB file 1F88) [6] was used as a template to
derive the constraints. The iterations consisted of a
cycle with three steps. (1) Examination of the pro-
tein structures and the output files from the previous
DIANA calculation. Constraint violations and van der
Waals clashes are detected. (2) Modifications of the
input files with angle and distance constraints. (3) DI-
ANA calculation with the modified constraints. The
NK antagonists were manually docked into the re-
ceptor models guided by published mutational data [4,
15, 28]. The receptor-ligand complex was minimised
with all hydrogens using the CHARMm force field
[29] with the adopted-basis Newton Raphson method,
a dielectric constant of 10 and 50–70 minimisation
steps.
Results and discussion
Construction of the pharmacophore models
As mentioned in the Introduction, our previously pub-
lished model [2] does not include hydrogen bond
acceptors in the head and tail fragments of NK2 ant-
agonists. Attempts to add a hydrogen bond acceptor
pharmacophore element to the head part proved futile
with the orientation of the pharmacophore elements
as in the previous model. Therefore we searched for
new orientations of the pharmacophore elements A
and B (Figure 2) for which a hydrogen bond acceptor
could be added to the model. Two new orientations
were found, leading to pharmacophore Models 2 and
3. The conformation of the flexible linker connecting
the head and tail fragments was retained as in the pre-
vious model. This conformation of the linker is the
same as in the global energy minimum of compound 2.
In all three models, pharmacophore elements B, C and
D are in the same positions as in our previous model
(Figure 2).
Compounds 1–3 (Figure 4) were used to derive
pharmacophore Models 2 and 3, whereas compounds
4–21 were used to evaluate the models. Compounds
1–3 were chosen due to their structurally diverse head
fragments. In compound 1 the pharmacophore ele-
ments A, B, E and F (Figure 1) are connected to
a six-membered ring containing an amide function-
ality, in compound 2 the pharmacophore elements
are connected by an open chain and in compound
3 an imidazole holds the pharmacophore elements.
Compound 3 is lacking pharmacophore element F.
Three conformations of each of compounds 1–3
were found for which pharmacophore elements A–D
could be superimposed. For the hydrogen bond accept-
ors in the head fragments, a dummy atom was placed
2.8 Å from the acceptor atom in the direction of the
lone pairs, thereby creating a vector (pharmacophore
elements E and F). One mode of superimposition
led to the previously published model. The hydrogen
bond acceptor-donor vectors (pharmacophore element
E and F) did not superimpose in these conformations.
However, for the other two modes of superimposition
(Models 2 and 3) the hydrogen bond acceptor-donor
vector did superimpose. In Models 2 and 3 the posi-
tions of the pharmacophore elements are defined as the
average coordinate of the pharmacophore elements in
the superimposition of compounds 1–3. The positions
of pharmacophore elements B, C and D are identical
in all three models.
Construction of pharmacophore element G
As evident from Figure 5 and Table 1, the heteroatoms
of the tail part of NK2 antagonists are important for the
affinity of the compounds. For instance, by comparing
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Figure 2. The previously published pharmacophore model. Left: arrangement of pharmacophore elements. Element C can be in an axial or
equatorial conformation. We propose that the equatorial conformation is most likely to be the bioactive conformation [2]. Center and right: the
putative bioactive conformations of (S)-2 with pharmacophore element C axial (center) and equatorial (right).
Table 1. Data of compounds fitted to pharmacophore Model 1. HB
acceptor angle is the deviation from the ideal hydrogen bond geo-
metry (ϕ as defined in Figure 3). IC50 is the NK2 affinity of the
racemate. Ki is the NK2 affinity of the highest affinity enantiomer.








2 [32, 39] 32.7 0.29 4.1 0.5
7 [39] 9.3 0.11 8.9
16 [40] 25.6 0.02 7.93
22 [39] 0 0.14 12
23 [39] 29.7 0.17 13
24 [39] 98.0 0.29 4.0
25 [39] 41.3 0.40 9.1
26 [41] 26.0 0.25 1.0
27 [39] 22.6 0.20 84
28 [39] 24.6 0.18 30
29 [41] 47.1 0.24 50
30 [41] 42.3 0.36 0.9
31 [41] 37.2 0.39 0.3




aThe fitting points are pharmacophore elements A–D and G.
compounds 2 and 34 it is obvious that a hydrogen-
bonding group in the tail is needed in order to obtain
Figure 3. Definition of the angle ϕ (the deviation from ideal hydro-
gen bond geometry). The head fragment of compound 4 is used as
an example. LP is the vector in the direction of the lone pair. F is
pharmacophore element F.
high NK2 affinity. Since a number of the high af-
finity NK2 antagonists do only have hydrogen bond
acceptors in the tail (e.g. compounds 7, 22, 27, 28,
30 and 31), the simplest would be to assume that the
interaction is one in which the receptor is the donor.
However, with our previous method for superimposi-
tion [2] all attempts to add a hydrogen bond acceptor
vector to the pharmacophore model failed because we
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Table 2. Data of compounds fitted to pharmacophore Models 2
and 3. Energy is the calculated conformational energy penalty for
the putative bioactive conformation. pKa values are for the amine
pharmacophore element D.
Cpd. Ref.
NK2 affinity Energy (kJ/mol)
pKa
IC50 (nM) Ki (nM) Model 2 Model 3
1 [43] N.A. N.A. 11.8 11.9 8.9
2 [32] 0.5 13.9 14.7 9.1
3 [44] 23 −5.3 8.4 9.0
4 [45] 3.0 9.5 7.6 8.9
5 [46] 23 −2.2 7.6
6 [47] 11 0.0 0.2 9.1
7 [39] 8.9 0.0 1.8 9.1
8 [48] 33 −0.8 9.6 10.1
9 [49] 4.5 14.2 40.4 9.2
10 [50] 1.6 43.3 86.7 9.2
11 [51] 0.1 27.8 31.2 9.1
12 [50] 1.3 33.1 52.6 9.1
13 [52] N. A. N.A. −4.5 9.6 9.0
14 [53] 0.5 67.5 102.0 7.6
15 [54] 0.6 8.3 0.0 8.3
16 [40] 7.93 5.2 −7.9 9.0
17 [55] 16.3 7.9 0.2 9.0
18 [56] N.A. N.A. 3.9 2.7 6.3
19 [57] 2.2 1.7 15.1 8.9
20 a [58] 4 51.7 38.0 –
20 b [58] 4 0 –
20aa [58] 4 −8.1 −1.3
21 [59] 8.9 6.2 0.5 9.0
a Conformation 1. b Conformation 2.
did not allow the vector to deviate from the ideal lone
pair direction. Therefore the procedure described in
the Computational methods section was adopted.
The tail fragments have the same conformation in
all three pharmacophore models, therefore the hydro-
gen bond interaction vector also has the same position
in the three models. Compounds 2, 7, 16, and 22–32
(Figure 5) were superimposed on the previous model
using pharmacophore elements A–D as fitting points.
A dummy atom was placed 2.8 Å from the hydro-
gen bond acceptor in the direction of the lone pair.
The coordinates of the hydrogen bond interaction vec-
tor (pharmacophore element G) were defined as the
average position of the acceptor and dummy atoms
respectively in the superimposition of compounds 2,
7, 16, and 22–32.
Pharmacophore Models 1–3 and the coordinates
of the pharmacophore elements are shown in Figures
6–8. Figure 9 shows a superimposition of the three
pharmacophore models. The positions of pharmaco-
phore elements B, C and D are identical in all three
models. In Model 1, pharmacophore elements A and
B are in a parallel displaced and tilted conformation.
In Model 2, pharmacophore elements A and B are in
a parallel displaced conformation, whereas they are in
an edge to ring face conformation in Model 3 [3].
Compounds and pharmacophore elements
The set of compounds 1–21 was chosen for its struc-
tural diversity and it contains high affinity selective
NK2, dual NK1/NK2 and triple NK1/NK2/NK3 ant-
agonists. Compounds 2–17 and 19–21 were also used
to derive or evaluate our previous model [2]. Two
or three hydrophobic groups are found in all NK2
antagonists (pharmacophore elements A, B and C;
Figure 1). A basic amino group is also present in all
structures (pharmacophore element D, represented as
a vector in Figure 2) except for compound 20 [2].
Pharmacophore elements A and B are connected by
a linker holding a hydrogen bond acceptor (pharma-
cophore elements E and F). In most cases this is a
carbonyl or ether oxygen. Furthermore, a hydrogen
bond acceptor is found in the tail part of most NK2
antagonists (pharmacophore element G). The hydro-
phobic groups are marked in Figure 4 by centroids, the
basic nitrogen is marked with a ‘+’ sign and the hy-
drogen bond acceptors are marked by bold type atom
labels.
The pharmacophore element labelled B (Figure 1)
is found to be an aromatic ring in all structures ex-
cept compounds 10–12. These compounds have elec-
tronegative groups in this area. Compound 10 has a
hydroxy group, compound 11 a methoxy group and
compound 12 a carbonyl group. The pharmacophore
element A does not need to be an aromatic ring but can
be aliphatic or olefinic hydrophobes as is the case for
compounds 1, 6, 14, and 15. In compounds 1, 14, and
15, the aromatic pharmacophore element C is lacking.
The hydrogen bond acceptor in the head fragment
(pharmacophore elements E and F) is present in all
compounds. Compounds 3 and 20 have only been fit-
ted to pharmacophore element E, whereas compounds
5 and 13 have only been fitted to pharmacophore ele-
ment F. The rest of the compounds could be fitted to
both pharmacophore elements E and F. However, in
the ligand-receptor complex, both interactions repres-
ented by the pharmacophore element E and F may not
be present (See section The receptor models below).
The hydrogen bond acceptor in the tail (pharmaco-
phore element G) is lacking in compounds 8, 10–12,
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Figure 4. Compounds 1–21 were fitted to the pharmacophore models. Centroids, ‘+’ and atoms in bold mark the selected pharmacophore
elements. The atoms in bold are hydrogen bond acceptors or donors. Data and references are given in Table 2.
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Figure 5. Compounds 2, 7, 16, 22–32 were used to derive the position of pharmacophore element G. Atoms in bold mark the selected hydrogen
bond acceptor pharmacophore elements. Data and references are given in Table 1.
15, and 20. The basic amino group is protonated
at physiological pH. pKa calculations using MolSurf
99/1 [30] (Table 2) show that in all compounds having
pharmacophore element D, this nitrogen always has
the highest pKa value.
Evaluation of the pharmacophore models
Compounds 2, 7, 16 and 22–32 (Figure 5) were fitted
to Model 1 by the procedure described under Compu-
tational methods. The angles (ϕ defined in Figure 3)
between the lone pair of the hydrogen bond acceptor
atom, and pharmacophore element G are shown in
Table 1 as well as the RMS values. It has been shown
that the direction of hydrogen bonds involving an ether
oxygen does not have a strong preference for the dir-
ection of the lone pairs [31]. The strength of the
hydrogen bond in the plane between the lone pairs
does not vary significantly with the angle ϕ. Hydro-
gen bonds involving a ketone oxygen have a lone pair
preference. However, this preference is small in the
plane between the lone pairs. A ϕ angle of 60◦ is cal-
culated to reduce the strength of the hydrogen bond
to approximately 80% compared to that of a hydrogen
bond in the lone pair direction [31]. Only compound
24 exceeds this deviation. A superimposition of the tail
fragments of compounds 2, 7, 16 and 22–32 is shown
in Figure 10.
Compounds 1–21 were fitted to both pharmaco-
phore Models 2 and 3 as described in the Computa-
tional methods section. RMS values and the deviations
of the hydrogen bond interaction vectors from the
ideal geometry are shown in Table 3. Figure 11 shows
a superimposition of compounds 1–9 and 13–21 fit-
ted to pharmacophore Model 2 (compounds 10–12 are
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Figure 6. Pharmacophore Model 1. Stereo image. The coordinates for the pharmacophore elements are shown in the box. G′ is the acceptor
atom of the hydrogen bond acceptor pharmacophore element. D′ is the hydrogen bond donor atom of the hydrogen bond donor pharmacophore
element.
Figure 7. Pharmacophore Model 2. Stereo image. The coordinates for the pharmacophore elements are shown in the box. E′ and G′ are the
acceptor atoms of the hydrogen bond acceptor pharmacophore elements. D′ is the hydrogen bond donor atom of the hydrogen bond donor
pharmacophore element.
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Figure 8. Pharmacophore Model 3. Stereo image. The coordinates for the pharmacophore elements are shown in the box. E′ and G′ are the
acceptor atoms of the hydrogen bond acceptor pharmacophore elements. D′ is the hydrogen bond donor atom of the hydrogen bond donor
pharmacophore element.
believed to have another binding mode, as described
below). Figure 12 shows a superimposition of the
same compounds fitted to pharmacophore Model 3.
Compounds 1–3, 6–8, 13, and 15, 16, 18 and 19
could be fitted to both Model 2 and 3 with low con-
formational energies and low RMS values (Tables 2
and 3). Compounds 4, 5, 9, 17, 20 and 21 have high
RMS values when calculated over all pharmacophore
elements. However, if pharmacophore element A is
excluded from the RMS calculation, these compounds
all have an acceptably low RMS value. Some com-
pounds have large substituents in the aromatic ring that
maps to pharmacophore element A (e.g. compounds
16 and 17) and some have a bulky aliphatic ring (e.g.
compounds 14 and 15). It is therefore reasonable to
assume that the centroid of pharmacophore element
A is not located exactly in the same place within the
receptor for all the compounds examined, but rather
falls within the same area.
We have previously shown that the force fields
MMFFs, MM2 and AMBER are unable to correctly
calculate the conformational energy penalty of com-
pound 14 due to an ‘electrostatic collapse’ [2]. Since
the structurally related compound 15 could be fitted
to both models with a low conformational energy, we
assume that compound 14 can also be fitted to both
models with a low conformational energy and that the
high calculated energy is a computational artefact.
Two conformations of compound 20 could be fit-
ted to pharmacophore Model 2. The main difference
between the conformations are the torsional angle of
the bond connecting the carbonyl carbon to the im-
idazole ring. In conformation 1, the carbonyl can be
superimposed on the carbonyl in the head fragment
of compound 2 whereas it is pointing in the oppos-
ite direction in conformation 2. Only conformations
for which the carbonyl is superimposable on com-
pound 2 can be fitted to Model 3. In compound 20,
the imidazole nitrogen is assumed to be involved in
hydrogen bonding to the receptor. The nitrogen can
be a hydrogen acceptor (unprotonated imidazole as
for compound 20) or donor (protonated imidazole as
in compound 20a in Table 2). Whether the nitrogen
acts as a donor or acceptor has a large impact on the
torsional energy of the bond connecting the carbonyl
carbon to the imidazole ring. A torsional drive of this
angle of the model system shown in Figure 13 was per-
formed by using MMFFs and B3LYP/6-31G∗∗. The
energy profile calculated by MMFFs compares well
with that of the DFT method for both the neutral and
protonated systems. The torsional barrier of the pro-
tonated system is lower than that of the neutral system,
and the profiles as calculated by both methods are dif-
ferent for the two model systems. When conformation
1 of compound 20 is fitted to Models 2 and 3 this
angle (defined in Figure 13 for the model system) is
144.3◦ and 131.2◦, respectively. By assuming that the
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Figure 9. Stereo image. A superimposition of pharmacophore Models 1–3. Black: the pharmacophore elements B, C, D and G have the same
position in the three models. Red: Model 1. Blue: Model 2. Green: Model 3.
imidazole acts as a hydrogen bond donor, 20a could be
fitted to both models with a low conformational energy
penalty. It is not unreasonable to assume that pharma-
cophore element E is a hydrogen bond donor as well as
an acceptor if the hydrogen bond is formed to a water
molecule or to a residue with a side chain that can act
as both hydrogen bond donor and acceptor. However,
compound 20 has a permanent positive charge, and
therefore it is unlikely to be protonated. This suggests
that conformation 2 is the bioactive conformation and
therefore compound 20 can be fitted to Model 2 but not
Model 3 with a low conformational energy penalty.
Compound 9 could be fitted to Models 2 and
3, but only to Model 2 with a low conformational
energy. Compound 21 could be fitted to Models 1
and 2 but not to Model 3. When fitted to Model
3 the ethyl substituent in the 2-position of the 2,3-
dihydro-isoindol-1-one group would fall in the area of
pharmacophore element A. The aromatic part of the
2,3-dihydro-isoindol-1-one group could only map the
pharmacophore model when the stereochemistry was
inverted at the 3-position, and the ring could not be fit-
ted in a coplanar orientation. Compounds 10–12 were
fitted to Model 1 with a low conformational energy
and a low RMS value [2]. However, they could only
be fitted to Models 2 and 3 with a high conformational
energy and high RMS. Structurally these compounds
differ from the rest as previously described.
The angle (ϕ defined in Figure 3) between the lone
pair of the hydrogen bond acceptor atom, and pharma-
cophore elements E, F and G is shown in Table 3. Only
compounds 9–12 have a large angle for pharmaco-
phore element E while the angle ϕ for pharmacophore
element G is large for compounds 4 and 18. The
angle ϕ for pharmacophore element D is also shown
in Table 3. Except for compounds 11–12 this angle is
small for all compounds.
If the amide in the head of compound 2 is de-
methylated, the affinity for the NK2R drops by more
than a factor of 200 [32]. There are three possible
explanations for this. (1) There could be a favourable
interaction between the methyl group and the receptor.
(2) The de-methylated compound has a more negative
solvation energy (by 13.9 kJ/mol using PM3/SM5.4
and by 5.1 kJ/mol using MMFFs+GB/SA) that is
not counteracted by a favourable interaction with
the receptor. (3) For compound 2 low energy con-
formations exist where the amide adopts either a cis
or a trans conformation. When compound 2 is de-
methylated only the trans conformation is found in
low energy conformations. A dihedral drive around
the amide gives a difference of 23.6 kJ/mol between
the cis and trans conformation whereas this differ-
ence is only 1.8 kJ/mol for the methylated compound
(MMFFs+GB/SA). Therefore the methyl group serves
to make the cis conformation energetically accessible.
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Figure 10. Superimposition of compounds 2, 7, 16 and 22–32. Stereo image, hydrogens are removed for clarity. The hydrogen bond acceptor
pharmacophore element G is shown as vectors.
If the third explanation is correct, Model 1 cannot
represent the actual binding mode.
Summarising the present section we suggest that
Model 2 represents the best pharmacophore model for
the examined NK2 antagonists. Model 2 includes all
the pharmacophore elements necessary for high affin-
ity and only compounds 10–12 could not be fitted to
this model with a low RMS and a low conformational
energy penalty. We believe that the compounds 10–12
bind to the receptor in a different mode.
The receptor models
It was verified that the NKR 7TM receptor models
were compatible with the zinc ion binding sites found
by Elling et al. [7, 8] and the Asp79Asn + Asn303Asp
double mutant by Donnelly et al. [9]. The compounds
were fitted to pharmacophore Model 2 before being
docked into the receptor model followed by minimisa-
tion of the ligand-receptor complex. The conformation
of the flexible linker connecting the head and tail
part of the antagonists was changed upon docking.
However, the conformational changes of the head and
tail fragments were minor. Conformations fitted to
pharmacophore Models 1 and 3 were found to be in-
compatible with the receptor models. Pharmacophore
element A was found to clash with the receptors in
conformations fitted to either Model 1 or 3.
The proposed antagonist binding sites of the NK1R
and NK2R models binding compound 16 are shown
in Figure 14. The residues identified by site directed
mutagenesis as important for the binding of compound
2 and 16 to the NK2R are M117, Q166, H198, Y266,
F270 and Y289 [4, 15, 28]. The residues important
for the binding of compound 16 to the NK1R are
Q165, H197, I204, F264 and H265 [4]. Compound
16 is docked in the NK2R model so that it makes a
direct interaction with the above mentioned residues.
In the NK1R model, compound 16 also has direct in-
teractions with the residues identified by site directed
mutagenesis. Furthermore, an interaction with Y287
is found. It is evident that the location of the bind-
ing site in our NK1R and NK2R models is the same
and that the conformations of the antagonists docked
into the NK1R and NK2R models are almost identical.
This conclusion is the opposite of that of Greenfeder
et al. [4] who conclude that the binding sites of the
NK1R and NK2R differ, and that the conformations
of compound 16 bound to the NK1R and the NK2R
are different.
Predictions made from the NKR models
When docked into the NK2R model the compounds
in this study except 10–12 were found to bind in a
conformation represented by pharmacophore Model 2.
However, the linker connecting the head and the tail
part of the antagonists has a different conformation
when docked in the NKRs as compared to the con-
formations fitted to Model 2. Therefore the head and
tail fragments have the same conformation but differ-
ent relative orientations in the docked conformations
as compared to pharmacophore Model 2. For each
pharmacophore element except F a favourable interac-
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Figure 11. Superimposition of compounds 1–9 and 13–21 fitted to Model 2. Stereo image, hydrogens are removed for clarity. The hydrogen
bond donor and acceptor pharmacophore elements D, E, F and G are shown as vectors.
tion with the receptor was identified. These are shown
in Figure 14. This suggests that pharmacophore Model
2 excluding pharmacophore element F represents the
actual binding mode.
The NK2R model and mutational data [28] indic-
ate that compounds 10–12 bind in the same area as the
rest of the compounds in this study, but in a different
orientation. Manual docking of compound 20a into
our NK2R model suggests that two hydrogen bonds
can be formed from Gln166 to the protonated nitrogen
and the benzyl oxygen. However, as discussed above
it is unlikely that compound 20 is protonated and it
is more reasonable to assume that only one hydrogen
bond is formed.
The NK2R model indicates that pharmacophore
element E interacts with a proton in the amide group
of the sidechain of Gln166 (Figure 14). Glutamine is a
flexible residue so the angle ϕ between the lone pair of
the ligand and the proton on Gln166 may be signific-
antly smaller than the value in Table 3. Pharmacophore
element G interacts with Tyr289 in the NK2R (Fig-
ure 14). Since tyrosine can act as both a hydrogen
bond donor and acceptor it is possible that Tyr289 in-
teracts with a hydrogen on the amide group in the tail
of compounds 4 and 18. This would result in a lower
ϕ value than given in Table 3. Pharmacophore element
D also interacts with a tyrosine (Tyr266 in the NK2R).
Therefore we are unable to conclude whether the basic
nitrogen is protonated or not when the ligands bind to
the receptor.
In the conformation of compound 2 docked into
the receptor models, the amide in the head fragment
is in a cis conformation. No specific interactions are
observed between the methyl group on the amide, and
the NK2R model. In the de-methylated analogue of
compound 2 specific interactions between the amide
and the NK2R model were also absent. Therefore the
role of the methyl group is either conformational (to
make the cis conformation energetically available) or
to lower the solvation energy.
Selectivity for the NK1, NK2 and NK3 receptors
The most important information provided by a phar-
macophore model is the putative bioactive conform-
ation of each ligand and the alignment of these con-
formations. A correct molecular alignment makes
it possible to identify the structural relationships
between different types of ligands. Receptor subtype
selectivity may arise either from differences in the
bioactive conformations at the receptor subtypes, or
from different substitution patterns. We believe the
latter is true for NK1/NK2 subtype selectivity. Table 4
shows the NK subtype selectivity for two head frag-
ments. Selective NK1, selective NK2, dual NK1/NK2
and triple NK1/NK2/NK3 antagonists can be obtained
from the same scaffold. The subtype selectivity is
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Table 3. Data of compounds fitted to pharmacophore Models 2 and 3. Angle is the deviation from ideal
hydrogen bond geometry (ϕ as defined in Figure 3).
Cpd.
Model 2 Model 3
Angle (˚) RMS Pharmacophore element RMS
D E F G (Åa) D E F G (Åa)
1 23.3 37.2 9.5 49.9 0.44 15.2 28.9 18.0 36.0 0.25
2 12.0 28.8 11.8 49.0 0.43 0.0 27.2 10.0 43.2 0.47
3 0.0 27.5 – 13.9 0.19 0.0 13.7 – 15.6 0.24
4 14.6 27.9 25.7 101.3 (0.60) 0.84 14.5 25.9 25.4 103.5 (0.41) 0.92
5 15.4 – 36.5 41.8 (0.47) 0.74 0.0 – 13.9 14.2 0.35
6 11.8 7.7 7.4 59.0 0.44 0.0 25.4 12.7 64.1 0.41
7 0.0 0.0 0.0 0.0 0.46 8.3 25.4 4.8 34.8 0.31
8 0.0 0.0 0.0 – 0.46 5.0 26.2 5.1 – 0.29
9 14.2 74.9 68.4 17.2 (0.52) 0.69 52.4 18.2 80.7 55.4 0.44
10 76.6 84.4 81.8 – 0.92 27.3 74.5 72.8 – 0.66
11 42.6 67.1 57.6 – 0.62 24.4 29.2 44.4 – (0.66) 1.52
12 40.1 8.9 80.0 – 1.08 66.6 57.5 37.2 – 0.56
13 13.9 – 39.2 37.0 (0.35) 0.63 0.0 – 16.5 22.2 0.29
14 11.8 32.6 23.0 27.6 (0.39) 0.63 30.8 49.2 14.1 51.3 0.40
15 13.2 33.5 20.6 39.3 0.48 52.9 54.9 0.0 6.8 0.35
16 20.3 35.2 51.8 39.9 0.46 20.0 31.8 13.7 14.5 (0.51) 0.86
17 17.0 21.0 14.6 31.3 (0.60) 0.89 17.3 29.6 14.8 13.6 (0.45) 0.76
18 26.2 35.7 23.3 77.0 0.27 20.4 18.2 3.3 82.2 0.45
19 18.7 25.9 99.6 55.5 (0.47) 0.56 5.8 9.8 55.4 30.2 0.71
20b – 40.5 – – (0.31) 0.92 – 49.4 – – 0.42
20c – 5.4 – – (0.26) 0.75
20ab – 5.1 – – (0.27) 0.74 – 17.8 – – (0.26) 0.82
21 14.0 37.4 25.9 – (0.61) 0.97 10.4 33.4 46.9 – (0.18)
aThe fitting points are pharmacophore elements A–G. Numbers in parentheses are RMS without pharma-
cophore element A as fitting point.
bConformation 1.
cConformation 2.
determined by the substitution pattern of the phar-
macophore elements A, B and C. An unsubstituted
phenyl ring and a 3,4-di-chlorophenyl as pharmaco-
phore elements A and B, respectively, is optimal for
NK2 activity [33, 34]. 3,5-Di-methylphenyl, 3,5-di-
trifluoromethylphenyl and 3,4,5-tri-methoxyphenyl as
pharmacophore element A is optimal for NK1 activ-
ity whereas substituents in pharmacophore element B
are of minor importance for NK1 activity [33, 35,
36]. Subtle changes around pharmacophore elements
C and G also seem to be important for subtype se-
lectivity. Of the different compounds examined only
compounds 10–12 and 21 have a scaffold that is not
claimed to have both NK1 and NK2 activities. We
concluded earlier that compounds 10–12 have another
binding mode than the rest of the compounds. The
head fragment of compound 21 is for NKR antag-
onists to our knowledge unique for this compound.
Therefore all the scaffolds (except one) from which
we have built the NK2 pharmacophore models can
also have NK1 activity. It is likely that the bioact-
ive conformations of the NK1R and NK2R subtypes
are very similar and that our pharmacophore mod-
els are dual NK1/NK2 pharmacophore models. This
is supported by the receptor model (Figure 14). In
the NK1R model, Thr201 is located in the binding
pocket for the trimethoxyphenyl group of compound
16. The equivalent residues in the NK2R and NK3R
are Ile202 and Ile252, respectively. Since threonine
is polar, as opposed to isoleucine, this could explain
the subtype difference in the observed SAR around
pharmacophore element A.
Reversing the amide group in the tail of compound
2 increases NK3 activity [37]. However, potent and se-
lective NK3 antagonists have a reversed amide group
in the linker holding pharmacophore elements A, B,
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Figure 12. Superimposition of compounds 1–9 and 13–21 fitted to Model 3. Stereo image, hydrogens are removed for clarity. The hydrogen
bond donor and acceptor pharmacophore elements D, E, F and G are shown as vectors.
Figure 13. Torsional drive of the angle 1-2-3-4 in the model system for the head fragment of compound 20.
E and F (cf. compound 2 with 37 and compound 19
with 36 in Figure 4 and Table 4) [37, 38]. Changing
the position of the carbonyl from that in compound 2
to that in 37 changes the conformational properties of
the head fragment considerably, but the change of the
carbonyl position from that in compound 19 to that
in 36 has only a minor effect on the conformations.
The selective NK3 antagonists also differ from the
NK2 antagonists in the length of the linker connect-
ing the head and the tail fragments. In the examined
NK2 antagonists (except compound 19) the linker is
a C2 chain whereas it is a C3 chain in the selective
NK3 antagonists. Compound 36 could be fitted to all
pharmacophore models while compound 37 could not
be fitted to any of the models. However, if pharma-
cophore elements E and F are ignored compound 37
can be fitted to Model 2. These observations suggest
that the bioactive conformations of NK antagonists at
the NK2R and NK3R subtypes could be different or
that the carbonyl in compound 37 is interacting with
another residue. Pharmacophore element E is forming
a hydrogen bond to Glu166 in the NK2R. The equiva-
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Table 4. SAR of two NK antagonist head fragments and two selective NK3 antagonists.
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Figure 14. Compound 16 docked into the NK1R model (top) and
NK2R model (bottom). Loops and the last three residues of helix
6 have been removed for clarity. Only sidechains identified by
site-directed mutagenesis to be important for antagonist binding as
well as residue Y287 in the NK1R are displayed.
lent residue in the NK3R is Glu218. When compound
2 is docked into the NK3R model a hydrogen bond
between pharmacophore element E and Glu218 is ob-
served. This interaction is not found for compound 37.
Instead pharmacophore element E of 37 can form a
hydrogen bond to Tyr256. However, while the bind-
ing sites of NK1R and NK2R have been extensively
explored by site directed mutagenesis, this is not the
case for NK3R.
Conclusions
Three pharmacophore models (Models 1–3) for NK
antagonists have been developed by use of a new pro-
cedure for treatment of hydrogen bonds during super-
imposition. The method results in more realistic RMS
values than if hydrogen bonds in the strict direction
of lone pairs were required and more pharmacophore
elements can be incorporated in the pharmacophore
models. Model 1 is identical to our previous model
except that a hydrogen bond acceptor pharmacophore
element has been added to the tail. The two novel
models (Models 2 and 3) consist of three hydrophobic
pharmacophore elements (A, B and C), a hydrogen
bond donor element (D), and three hydrogen bond
acceptor elements (E, F and G). The hydrogen bond
donor-acceptor interactions are represented as vectors.
In Model 2, the antagonists bind in an extended con-
formation with pharmacophore elements A and B in
a parallel displaced conformation. In Model 3, phar-
macophore elements B, C, D and G are in the same
arrangement as in Model 1 and 2, but pharmaco-
phore elements A and B are in an edge to ring face
conformation.
Pharmacophore Model 2 and 3 models were eval-
uated against 21 structurally diverse, high affinity
selective NK2, dual NK1/NK2 and NK1/NK2/NK3
antagonists. All compounds except five could be fit-
ted to both models with a low conformational energy
penalty and low RMS value. We believe that three
of the remaining five compounds have another bind-
ing mode. The last two compounds could be fitted
to Model 2 but not Model 3. Therefore we suggest
that Model 2 represents the actual binding mode for
the examined NK2 antagonists. This conclusion is
supported by our receptor model study. Compounds
fitted to pharmacophore Model 2 but not to Mod-
els 1 and 3 could be docked in the receptor models
with only minor changes to the conformation of the
head and tail fragments. The flexible linker connecting
the fragments has another conformation in the docked
conformations compared with pharmacophore Model
2. For each pharmacophore element except F, a spe-
cific interaction with the NK2R model was observed.
This binding mode is compatible with published site
directed mutagenesis data.
The new pharmacophore model (Model 2) repres-
ents a significant improvement in the description of the
receptor binding properties of NK receptor antagonists
compared to previously reported models. The larger
number of pharmacophore elements in the new model
should be an advantage in database searching for novel
NK receptor ligands.
The NK1/NK2 subtype selectivity is determined
by the substitution pattern of the pharmacophore ele-
ments A, B, C and G and not by differences in
the bioactive conformations at the receptor subtypes.
Therefore our pharmacophore models can be used for
the design of both potent and selective NK1 and NK2
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antagonists. However, we believe that NK2/NK3 sub-
type selectivity is determined by either differences in
the bioactive conformations at the receptor subtypes
or that pharmacophore element E is interacting with
different residues in the two receptor subtypes. These
findings are also supported by our NK1R, NK2R and
NK3R model study.
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